• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    CareDx (CDNA) Showcased AlloSure Kidney Data, Is The Stock Fully Priced?

    Simply Wall St·10/28/2026 04:59:23
    Listen to the news

    CareDx event puts AlloSure Kidney in the spotlight

    CareDx (CDNA) moved back into focus after new AlloSure Kidney data at ASN Kidney Week 2026 linked donor derived cell free DNA levels to kidney transplant graft injury risk in real world patient cohorts.

    Investors already had CareDx on their radar after a very large 3-year total shareholder return of about 12x. The latest AlloSure Kidney data arrives after a 90-day share price return of 85.12% and a year-to-date gain of 268.50%, suggesting momentum has been building even before this week’s ASN spotlight.

    Scan for other transplant and diagnostics stocks showing similar momentum and payer traction to CareDx by checking the hand picked 34 healthcare AI stocks now shaping the next wave of organ health tools.

    After a move like CareDx has posted, the debate quickly shifts. Is this a case of chasing a story that has mostly played out, or paying up for earnings power that still is not fully reflected in the valuation?

    Most Popular Narrative: 9.9% Overvalued

    CareDx last closed at $70.53, while the most followed narrative pegs fair value at $64.17. The current price sits above that assessment and raises questions about how much future growth is already reflected in the valuation.

    “The launch of AI-driven diagnostics like AlloSure Plus and integration into electronic health record systems (e.g., EPIC) positions CareDx to benefit from the broader adoption of precision medicine and personalized diagnostics, potentially boosting adoption rates, aiding reimbursement, and ultimately supporting net margin improvements.”

    See why 7 investors see CareDx as 10% overvalued.

    Result: Fair Value of $64.17 (OVERVALUED)

    Still, two pressure points sit in the background for CareDx: potential LCD reimbursement changes and the Naveris integration, both capable of quickly rewiring this upbeat narrative.

    Find out about the key risks to this CareDx narrative.

    Another View: CareDx on earnings multiples

    Analyst narratives frame CareDx as modestly overvalued around a fair value of $64.17. From a different perspective, the stock trades on a P/E of 32.9x, below peers at 35.8x but steep versus its own fair ratio of 11.2x. That gap points to meaningful valuation risk if sentiment cools.

    For a closer look at how this earnings multiple compares with peers and the fair ratio the market could move toward, See what the numbers say about this price — find out in our valuation breakdown.

    NasdaqGM:CDNA P/E Ratio as at Oct 2026
    NasdaqGM:CDNA P/E Ratio as at Oct 2026

    Next Steps

    If this CareDx story seems finely balanced between promise and risk, promptly conduct your own research and carefully test both the numbers and the narrative. You can start by weighing the 2 key rewards and 3 important warning signs

    Looking for more CareDx style investment ideas?

    Do not stop your research with CareDx. Broaden your watchlist with fresh candidates that fit different risk profiles and income needs so opportunities do not slip past you.